君實生物(688180.SH):目前民得維®已被納入臨時國家醫保藥品目錄,正持續推進渠道佈局和進院工作
格隆匯6月8日丨有投資者向君實生物(688180.SH)提問,“公司新冠特效藥,在各大醫院備庫率極低,極難購買,在美團等線上渠道又無法享受醫保,且價格是國產藥中最貴的。望公司能夠及時改善銷售渠道和定價策略。另希望公司能多為廣大股東利益和健康考慮,與美團等線上平台合作,給患有新冠的股東提供至少一次免費用藥的福利。一方面讓股東及時免於新冠的病痛,改善持股體驗,另一方面也能為公司銷售獲取流量。公司目前的股價讓廣大股東在二級市場的平均損失已遠超藥價,寒心。”
君實生物回覆稱,目前民得維®已被納入臨時國家醫保藥品目錄,公司正在持續推進該產品的渠道佈局和進院工作,以期提高藥物可及性,讓更多患者獲益。此外,本着對患者生命安全負責的原則,我們也會在政策法規範圍內最大程度地為患者用藥提供便利。民得維?目前為處方藥,必須憑執業醫師或執業助理醫師處方才可調配、購買和使用。有需要的患者可以撥打熱線電話400-008-0866(北京時間9:00-17:30)瞭解相關醫療機構信息,也可通過線上平台(如美團、阿里、京東等)進行問診諮詢購藥。謝謝您的建議,我們也會將您提到的相關意見向公司管理層及時反饋。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.